|
Comparison of the application value of spiral computed tomography and x-ray examination in the differential diagnosis of lung cancer and benign lung tumors
|
B. He   , J. Xu , L. Wang , B. Li , X. Xu |
| epartment of Radiology, the Affiliated Hospital of Shaoxing University (Shaoxing Municipal Hospital), Shaoxing 312000, Zhejiang Province, China , 472184496@qq.com |
|
|
Abstract: (210 Views) |
Background: The differential diagnosis of lung cancer (LC) and benign lung tumors is challenging in clinic. Spiral computed tomography (CT) and X-ray are commonly utilized imaging techniques. Accordingly, the practical significance of CT and X-ray imaging in the differential identification of benign versus malignant pulmonary neoplasms was explored. Materials and Methods: A retrospective analysis was performed on data from 105 patients who had undergone both CT and X-ray examinations to evaluate variations in peripheral blood tumor markers. The imaging features of benign and malignant lung tumors were compared, and the diagnostic efficacy of CT and X-ray was assessed. Results: CT examination of patients with unilateral lung tumors or lung insufficiency demonstrated a greatly higher detection rate of speculated lesions compared to X-ray. Additionally, tumor markers showed a positive correlation with tumor size. The positive rate for differential diagnosis using CT was notably superior to that of X-ray (P<0.05). The sensitivity (Sen), specificity (Spe), accuracy (Acc), positive predictive value, and negative predictive value of CT and X-ray in differential diagnosis were 86.4%, 68.3%, 94.9%, 74.4%, 89.5%, 70.5%, 96.6%, 81.8%, 80.4%, and 58.0%, respectively. CT was considerably more valuable for differential diagnosis (P<0.05). Conclusion: X-ray and CT scans serve as pivotal diagnostic tools for distinguishing between benign and malignant pulmonary neoplasms. CT has a better effect in the differential diagnosis of lung tumors, and its imaging performance is more comprehensive, which is worthy of clinical application. |
|
| Keywords: lung tumor, CT, X-ray, differential, diagnosis. |
|
|
Full-Text [PDF 923 kb]
(82 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. Gu M, Chen Z, Xiong H, Liu K, Ye Z, You Q (2022) Role and clinical significance of LncRNA16 in the malignant proliferation of lung cancer cells. Cell Mol Biol, 68(7): 177-181. DOI: 10.14715/cmb/2022.68.7.29 [ DOI:10.14715/cmb/2022.68.7.29] 2. Wang W, Ma M, Li L, et al. (2022) MTA1-TJP1 interaction and its involvement in non-small cell lung cancer metastasis. Transl Oncol, 25: 101500. DOI:10.1016/j.tranon.2022.101500 [ DOI:10.1016/j.tranon.2022.101500] 3. Zhang S, Li D, Han X (2023) Systematic evaluation of clinical efficacy of CYP1B1 gene polymorphism in EGFR mutant non-small cell lung cancer observed by medical image. Open Life Sci, 18(1): 20220688. DOI:10.1515/biol-2022-0688 [ DOI:10.1515/biol-2022-0688] 4. Bradley JD, Hu C, Komaki RR, et al. (2020) Long-term results of NRG Oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol, 38(7): 706-714. DOI:10.1200/JCO.19.01162 [ DOI:10.1200/JCO.19.01162] 5. He S, Li H, Cao M, et al. (2022) Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China. Transl Lung Cancer Res, 11(8): 1591-1605. DOI:10.21037/tlcr-22-240 [ DOI:10.21037/tlcr-22-240] 6. Yu L, Zhang B, Zou H, et al. (2022) Multivariate analysis on development of lung adenocarcinoma lesion from solitary pulmonary nodule. Contrast Media Mol Imaging, 2022: 8330111. DOI:10.1155/2022/8330111 [ DOI:10.1155/2022/8330111] 7. Kang Y, Lee SE, Kim CH, Lee YJ (2024) Revisiting the impact of clinicopathologic characteristics in PD-L1 profile in a large cohort of non-small cell lung cancer. Transl Lung Cancer Res, 13(3): 475-490. DOI:10.21037/tlcr-23-812. [ DOI:10.21037/tlcr-23-812] 8. Nooreldeen R and Bach H (2021) Current and future development in lung cancer diagnosis. Int J Mol Sci, 22(16): 8661. DOI:10.3390/ijms22168661. [ DOI:10.3390/ijms22168661] 9. Sullivan FM, Mair FS, Anderson W, et al. (2021) Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. Eur Respir J, 57(1): 2000670. DOI:10.1183/13993003.00670-2020 [ DOI:10.1183/13993003.00670-2020] 10. Robles-Zurita JA, McMeekin N, Sullivan F, Mair FS, Briggs A (2024) Health economic evaluation of lung cancer screening using a diagnostic blood test: The Early Detection of Cancer of the Lung Scotland (ECLS). Curr Oncol, 31(6): 3546-3562. DOI:10.3390/curroncol31060261 [ DOI:10.3390/curroncol31060261] 11. Neshastehriz A, Hormozi-Moghaddam Z, Amini S, Taheri S, Abedi Kichi Z. (2024) Combined sonodynamic therapy and X-ray radiation with methylene blue and gold nanoparticles coated with apigenin: Impact on MCF7 cell viability. Int J Radiat Res, 22 (2): 509-513. DOI:10.52547/ijrr.21.24 [ DOI:10.61186/ijrr.22.2.515] 12. Chen L, Dong S, Chen Y, Tian L, He C, Tao S (2024) Diagnostic value of chest computed tomography scan based on artificial intelligence and deep learning in children with lobar pneumonia and analysis of image features before and after treatment: A retrospective cohort study. Int J Radiat Res, 22 (1): 199-205. DOI: 10.52547/ijrr.21.28 [ DOI:10.61186/ijrr.22.1.199] 13. Cao S and Shu Z (2024) Spectral CT based radiomics for predicting brain metastases in patients with lung cancer. Int J Radiat Res, 22(2): 347-353. DOI:10.61186/ijrr.22.2.347 [ DOI:10.61186/ijrr.22.2.347] 14. Seijo LM, Peled N, Ajona D, et al. (2019) Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol, 14(3): 343-357. DOI:10.1016/j.jtho.2018.11.023. [ DOI:10.1016/j.jtho.2018.11.023] 15. RM. Zhou, ZH. Cai, YR. Yuan, et al. (2024) Study on the application value of combined detection of multiple tumor markers in lung cancer classification diagnosis, Int J Radiat Res, 22 (2): 283-287. DOI:10.61186/ijrr.22.2.283 [ DOI:10.61186/ijrr.22.2.283] 16. Schabath MB and Cote ML (2019) Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev, 28(10): 1563-1579. DOI:10.1158/1055-9965.EPI-19-0221 [ DOI:10.1158/1055-9965.EPI-19-0221] 17. Godoy MCB, Lago EAD, Pria HRFD, Shroff GS, Strange CD, Truong MT (2022) Pearls and pitfalls in lung cancer CT screening. Semin Ultrasound CT MR, 43(3): 246-256. DOI:10.1053/j.sult.2022.03.002 [ DOI:10.1053/j.sult.2022.03.002] 18. Manapov F, Eze C, Holzgreve A, et al. (2022) PET/CT for target delineation of lung cancer before radiation therapy. Semin Nucl Med, 52(6): 673-680. DOI:10.1053/j.semnuclmed.2022.05.003 [ DOI:10.1053/j.semnuclmed.2022.05.003] 19. Al-Umairi R, Tarique U, Moineddin R, et al. (2022) CT patterns and serial CT changes in lung cancer patients post stereotactic body radiotherapy (SBRT). Cancer Imaging. 22(1): 51. DOI:10.1186/s40644-022-00491-1 [ DOI:10.1186/s40644-022-00491-1] 20. Lee HY, Oh YL, Park SY (2021) Hyperattenuating adrenal lesions in lung cancer: biphasic CT with unenhanced and 1-min enhanced images reliably predicts benign lesions. Eur Radiol, 31(8): 5948-5958. DOI:10.1007/s00330-020-07648-1 [ DOI:10.1007/s00330-020-07648-1] 21. Tamponi M, Crivelli P, Montella R, et al. (2021) Exploring the variability of radiomic features of lung cancer lesions on unenhanced and contrast-enhanced chest CT imaging. Phys Med, 82: 321-331. DOI:10.1016/j.ejmp.2021.02.014. [ DOI:10.1016/j.ejmp.2021.02.014] 22. Luo C, Song Y, Liu Y, et al. (2022) Analysis of the value of enhanced CT combined with texture analysis in the differential diagnosis of pulmonary sclerosing pneumocytoma and atypical peripheral lung cancer: a feasibility study. BMC Med Imaging, 22(1): 16. doi:10.1186/s12880-022-00745-1 [ DOI:10.1186/s12880-022-00745-1] 23. Larici AR, Franchi P, Del Ciello A, et al. (2021) Role of delayed phase contrast-enhanced CT in the intra-thoracic staging of non-small cell lung cancer (NSCLC): What does it add? Eur J Radiol, 144: 109983. DOI:10.1016/j.ejrad.2021.109983 [ DOI:10.1016/j.ejrad.2021.109983] 24. Bianconi F, Palumbo I, Fravolini ML, et al. (2022) Form factors as potential imaging biomarkers to differentiate benign vs. malignant lung lesions on CT scans. Sensors, 22(13): 5044. DOI:10.3390/s22135044 [ DOI:10.3390/s22135044] 25. Bradley SH, Bhartia BS, Callister ME, et al. (2021) Chest X-ray sensitivity and lung cancer outcomes: a retrospective observational study. Br J Gen Pract, 71(712): e862-e868. DOI:10.3399/BJGP.2020.1099 [ DOI:10.3399/BJGP.2020.1099] 26. Bradley SH, Hatton NLF, Aslam R, et al. (2021) Estimating lung cancer risk from chest X-ray and symptoms: a prospective cohort study. Br J Gen Pract, 71(705): e280-e286. DOI:10.3399/bjgp20X713993 [ DOI:10.3399/bjgp20X713993] 27. Beck KS, Sung YE, Lee KY, Han DH (2020) Invasive mucinous adenocarcinoma of the lung: Serial CT findings, clinical features, and treatment and survival outcomes. Thorac Cancer, 11(12): 3463-3472. DOI:10.1111/1759-7714.13674 [ DOI:10.1111/1759-7714.13674] 28. Sevillano D, Núñez LM, Chevalier M, García-Vicente F (2020) Definition of internal target volumes based on planar X-ray fluoroscopic images for lung and hepatic stereotactic body radiation therapy. Comparison to inhale/exhale CT technique. J Appl Clin Med Phy, 21(8): 56-64. DOI10.1002/acm2.12914 [ DOI:10.1002/acm2.12914] 29. Pan J, Zhou C, Zhao X, et al. (2018) A two-miRNA signature (miR-33a-5p and miR-128-3p) in whole blood as potential biomarker for early diagnosis of lung cancer. Sci Rep, 8(1): 16699. DOI:10.1038/s41598-018-35139-3 [ DOI:10.1038/s41598-018-35139-3] 30. Osmani L, Askin F, Gabrielson E, Li QK (2018) Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol, 52(Pt 1): 103-109. DOI:10.1016/j.semcancer.2017.11.019. [ DOI:10.1016/j.semcancer.2017.11.019] 31. Du K, Li Q, Huang J, et al. (2024) An increase of serum CA-125 to two times of nadir level strongly predicts the image-identified relapse of serous ovarian cancer. Sci Rep, 14(1): 14986. DOI:10.1038/s41598-024-65760-4 [ DOI:10.1038/s41598-024-65760-4] 32. Chen XK, Gu CL, Fan JQ, Zhang XM. (2020) P-STAT3 and IL-17 in tumor tissues enhances the prognostic value of CEA and CA125 in patients with lung adenocarcinoma. Biomed Pharmacother. 125: 109871. DOI:10.1016/j.biopha.2020.109871 [ DOI:10.1016/j.biopha.2020.109871] 33. Li G, Zhang H, Zhang L, et al. (2024) Serum Markers CA125, CA153, and CEA along with inflammatory cytokines in the early detection of lung cancer in high-risk populations. Biomed Res Int, 2024: 9827549. DOI:10.1155/2022/1394042 [ DOI:10.1155/2022/1394042] 34. Li X, Xu Y, Zhang L (2019) Serum CA153 as biomarker for cancer and noncancer diseases. Prog Mol Biol Transl Sci, 162: 265-276. DOI:10.1016/bs.pmbts.2019.01.005 [ DOI:10.1016/bs.pmbts.2019.01.005] 35. Jiang C, Zhao M, Hou S, et al. (2022) The indicative value of serum tumor markers for metastasis and stage of non-small cell lung cancer. Cancers, 14(20): 5064. DOI:10.3390/cancers14205064 [ DOI:10.3390/cancers14205064] 36. Dal Bello MG, Filiberti RA, Alama A, et al. (2019) The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. J Transl Med, 17(1): 74. DOI:10.1186/s12967-019-1828-0 [ DOI:10.1186/s12967-019-1828-0] 37. Mao X, Liu J, Hu F, et al. (2022) Serum NSE is early marker of transformed neuroendocrine tumor after EGFR-TKI treatment of lung adenocarcinoma. Cancer Manag Res, 14: 1293-1302. DOI:10.2147/CMAR.S349082 [ DOI:10.2147/CMAR.S349082] 38. Zhou W, Yang Y, Wang Z, Liu Y, Lari Najafi M (2023) Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on lung cancer patients. J Healthc Eng, 2023: 9796148. DOI:10.1155/2021/6929971 [ DOI:10.1155/2021/6929971] 39. Xi C, Jiang H, Xue Y, Lv Y, Wang C (2023) Effects of Bevacizumab combined with chemotherapy on CT, CyFRA21-1, and ProGRP and prognosis of lung cancer patients under nursing intervention. Comput Math Methods Med, 2023: 9805719. doi:10.1155/2022/9422902. [ DOI:10.1155/2022/9422902] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
He B, Xu J, Wang L, Li B, Xu X. Comparison of the application value of spiral computed tomography and x-ray examination in the differential diagnosis of lung cancer and benign lung tumors. Int J Radiat Res 2025; 23 (2) :341-347 URL: http://ijrr.com/article-1-6392-en.html
|
